Subodh Verma: Tirzepatide Improves Multiple Cardiovascular Risk Pathways
Subodh Verma, Heart Surgeon-Scientist at Unity Health Toronto, Professor and Canada Research Chair, CV Surgery at Temerty Medicine, shared a post on X about a recent article he and his colleagues co-authored, published in JACC, adding:
“Delighted to share this new JACC analysis from SURMOUNT-1.
Over 72 weeks, we saw improvements across multiple pathways linked to cardiovascular risk – including inflammation, insulin resistance, adiposity and hepatic stress, endothelial dysfunction, and thrombosis.
At the 15-mg dose of Tirzepatide, placebo-adjusted changes included a 55% reduction in hsCRP, 30% reduction in IL-6, 39% reduction in HOMA-IR, 61% reduction in leptin, and 44% reduction in PAI-1, with adiponectin increasing by 48%.”
Title: Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis
Authors: Naveed Sattar, Bruno Linetzky, Giacomo Ruotolo, Subodh Verma, Harald Sourij, Hui Wang, Kadie Vanderman, Jonathan M. Wilson, Ryan M. Griffin, Adam Stefanski, Paul M. Ridker
Stay updated on all scientific advnaces with Hemostasis Today.
-
Aug 18, 2026, 19:49Make the Most of Your Summer and Catch Up on Gene Therapy – EAHAD
-
Aug 18, 2026, 19:46Lesley Van Wyk: ANA Testing – From Screening to Interpretation
-
Aug 18, 2026, 19:45Factor IV – The ‘Coagulation Factor’ That Isn’t a Protein – ICHCC
-
Aug 18, 2026, 19:42Melanie Jay: What Should Behavioral Support Look Like Alongside Obesity Medications?
-
Aug 18, 2026, 19:37Boby Varkey Maramattom: Thrombolysis in Acute Ischemic Stroke With an Unruptured Aneurysm
-
Aug 18, 2026, 19:35Kelly Anderson: Factor XIa Inhibition for Secondary Stroke Prevention
-
Aug 18, 2026, 19:33Nebil Youssef: Deaths in Custody Raise New Questions for Syria’s Government
-
Aug 18, 2026, 19:32Ihab Suliman: A Snake Venom Helping Diagnose an Autoimmune Clotting Disorder?
-
Aug 18, 2026, 16:57New Insights Into Hemophilic Arthropathy – CRH French Reference Center for Hemophilia Lyon